Her2 genotype and breast cancer progression in Korean women
- PMID: 15693849
- DOI: 10.1111/j.1440-1827.2005.01789.x
Her2 genotype and breast cancer progression in Korean women
Abstract
The amplification and overexpression of Her2 proto-oncogene have been found to be associated with the development and progression of human breast cancer. A polymorphic valine allele at codon 655 of the Her2 gene (Her2(V655)) was suggested by some authors to be a susceptible genetic factor for the development of breast cancer. The Her2 polymorphism at codon 655 was investigated in 304 Korean women including 177 patients with breast cancer. The association between Her2 genotype and Her2 protein overexpression was also examined in breast cancers by immunohistochemistry. Her2(V655) was not associated with a significant breast cancer risk (odds ratio (OR), 1.792; 95% confidence interval (CI), 0.459-6.991). The frequency of homozygous or heterozygous valine allele increased in stage 2 patients (OR, 1.67; 95% CI, 0.67-4.19), and patients in stages 3 and 4 (OR, 3.36; 95% CI, 0.85-13.42) compared to patients in stage 0. However, an association between the presence of the valine allele and the overexpression of Her2 protein could not be demonstrated. These results suggest that Her2 polymorphism at codon 655 is not associated with the development of breast cancer in Korean women. However, there is a possibility that the valine allele at codon 655 might be related to increased risk of breast cancer progression.
Similar articles
-
P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer.J Exp Clin Cancer Res. 2007 Mar;26(1):133-40. J Exp Clin Cancer Res. 2007. PMID: 17550142
-
Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.Neoplasma. 2008;55(2):87-95. Neoplasma. 2008. PMID: 18237245
-
HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis.Breast Cancer Res Treat. 2009 Mar;114(2):371-6. doi: 10.1007/s10549-008-0010-9. Epub 2008 Apr 26. Breast Cancer Res Treat. 2009. PMID: 18438707
-
HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.Histopathology. 2006 May;48(6):702-7. doi: 10.1111/j.1365-2559.2006.02403.x. Histopathology. 2006. PMID: 16681686
-
[ERBB: an exemplary family].Ann Pathol. 1999 Apr;19(2):91-3. Ann Pathol. 1999. PMID: 10349471 Review. French. No abstract available.
Cited by
-
HER2Ile655Val Single Nucleotide Polymorphism Associated with Early-Onset Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis.Asian Pac J Cancer Prev. 2021 Jan 1;22(1):11-18. doi: 10.31557/APJCP.2021.22.1.11. Asian Pac J Cancer Prev. 2021. PMID: 33507673 Free PMC article.
-
HER2 Ile655Val and PTEN IVS4 polymorphisms in patients with breast cancer.Mol Biol Rep. 2013 Feb;40(2):1813-8. doi: 10.1007/s11033-012-2235-2. Epub 2012 Oct 21. Mol Biol Rep. 2013. PMID: 23086302
-
Dataset reporting detection of breast cancer-related HER2I655V polymorphism using allele-specific polymerase chain reaction.Data Brief. 2016 Sep 24;9:689-695. doi: 10.1016/j.dib.2016.09.033. eCollection 2016 Dec. Data Brief. 2016. PMID: 27790634 Free PMC article.
-
Her2 Ile655Val polymorphism and its association with breast cancer risk: an updated meta-analysis of case-control studies.Sci Rep. 2018 May 9;8(1):7427. doi: 10.1038/s41598-018-25769-y. Sci Rep. 2018. PMID: 29743533 Free PMC article.
-
The genetic polymorphisms of HER-2 and the risk of lung cancer in a Korean population.BMC Cancer. 2008 Dec 4;8:359. doi: 10.1186/1471-2407-8-359. BMC Cancer. 2008. PMID: 19055823 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous